Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Non-Current Assets (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Non-Current Assets for 6 consecutive years, with $83.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 59.1% to $83.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $298.9 million through Dec 2025, up 42.43% year-over-year, with the annual reading at $83.1 million for FY2025, 59.1% up from the prior year.
  • Non-Current Assets for Q4 2025 was $83.1 million at Lexicon Pharmaceuticals, roughly flat from $83.4 million in the prior quarter.
  • The five-year high for Non-Current Assets was $83.4 million in Q3 2025, with the low at $51.9 million in Q1 2025.
  • Average Non-Current Assets over 3 years is $60.1 million, with a median of $52.9 million recorded in 2023.
  • Peak annual rise in Non-Current Assets hit 59.1% in 2025, while the deepest fall reached 1.34% in 2025.
  • Over 3 years, Non-Current Assets stood at $52.9 million in 2023, then decreased by 1.24% to $52.2 million in 2024, then skyrocketed by 59.1% to $83.1 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $83.1 million, $83.4 million, and $80.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.